MedTrace Logo

Neoadjuvant Combination Immunotherapy for Stage III Melanoma

NCT03842943 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2024-05-02

No results posted yet for this study

Summary

Determine safety and efficacy of pre-operative combination immunotherapy with Talimogene Laherparepvec (T-VEC)/Pembrolizumab given prior to complete lymph node dissection in resectable stage 3 cutaneous melanoma with clinically apparent lymph node metastases.

Conditions

Interventions

DRUG

Pembrolizumab

Preoperative infusions

DRUG

Talimogene Laherparepvec

Preoperative intralesional injection

Sponsors & Collaborators

  • University of Louisville

    lead OTHER

Principal Investigators

  • Michael Egger, MD · University of Louisville

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-03
Primary Completion
2026-06-01
Completion
2028-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03842943 on ClinicalTrials.gov